Charles River Laboratories International, Inc. (NYSE:CRL) Stock Has Consensus Target Price of $302.33

Charles River Laboratories International, Inc. (NYSE:CRL) has been given an average recommendation of “Moderate Buy” by the seventeen ratings firms that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have issued a buy rating and two have issued a strong buy rating on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $302.33.

A number of equities research analysts have commented on the company. Barclays lifted their target price on Charles River Laboratories International from $300.00 to $330.00 and gave the company an “overweight” rating in a research report on Friday, September 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Charles River Laboratories International in a report on Monday, September 28th. Zacks Research raised Charles River Laboratories International from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 2nd. CLSA lowered shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price objective on the stock. in a research report on Monday, July 20th. Finally, BNP Paribas Exane set a $250.00 price target on shares of Charles River Laboratories International in a research note on Wednesday, July 1st.

Insider Buying and Selling

In other news, Director James Foster sold 33,561 shares of the company’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $300.00, for a total transaction of $10,068,300.00. Following the completion of the sale, the director directly owned 31,596 shares in the company, valued at $9,478,800. This represents a 51.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Shannon M. Parisotto sold 5,046 shares of the stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $263.00, for a total value of $1,327,098.00. Following the completion of the transaction, the executive vice president directly owned 4,807 shares in the company, valued at $1,264,241. This trade represents a 51.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 118,169 shares of company stock valued at $35,191,216. Company insiders own 1.30% of the company’s stock.

Hedge Funds Weigh In On Charles River Laboratories International

A number of large investors have recently modified their holdings of CRL. Amundi raised its holdings in Charles River Laboratories International by 175.2% in the first quarter. Amundi now owns 773,315 shares of the medical research company’s stock valued at $133,397,000 after buying an additional 492,301 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Charles River Laboratories International by 14.6% in the first quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company’s stock worth $285,001,000 after acquiring an additional 210,260 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in shares of Charles River Laboratories International by 230.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 204,537 shares of the medical research company’s stock valued at $59,044,000 after acquiring an additional 142,716 shares during the period. State of Alaska Department of Revenue raised its stake in shares of Charles River Laboratories International by 2,268.2% in the 3rd quarter. State of Alaska Department of Revenue now owns 111,781 shares of the medical research company’s stock valued at $32,977,000 after acquiring an additional 107,061 shares during the period. Finally, Ranger Investment Management L.P. acquired a new position in shares of Charles River Laboratories International during the 1st quarter valued at $12,198,000. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Charles River Laboratories International Trading Up 0.5%

Charles River Laboratories International stock opened at $359.05 on Friday. The business’s 50-day simple moving average is $297.15 and its two-hundred day simple moving average is $220.07. Charles River Laboratories International has a fifty-two week low of $146.20 and a fifty-two week high of $359.89.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $980.53 million. The business’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same period in the previous year, the company posted $3.12 EPS. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, analysts expect that Charles River Laboratories International will post 11.38 earnings per share for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.